Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 40Recurrence 9Neoplasms, Plasma Cell 7Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, B-Cell 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Epstein-Barr Virus Infections 1Disease Progression 1Disease 1Central Nervous System Neoplasms 1Amyloidosis 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × pomalidomide × Clear all
NCT05389423 2026-04-28

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

University of Michigan Rogel Cancer Center

Phase 1 Not yet recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT01722305 2019-07-22

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Mayo Clinic

Phase 1 Completed
29 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡